The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.
about
Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.TIC10/ONC201: a bend in the road to clinical developmentIdentification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathwayFirst-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer AgentSmall Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.Discovery and clinical introduction of first-in-class imipridone ONC201.Neuro-oncology biotech industry progress report.ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.ONC201: a new treatment option being tested clinically for recurrent glioblastomaFerrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure⁻Activity Relationships
P2860
Q33709701-91E89F20-2C4D-48D0-8C6C-96BBE6C10BA3Q35238939-6AF450D9-B645-474C-9EAD-708615914861Q35595688-86AF7E4D-ADF0-4CAC-A9FE-35DA52B44560Q35844988-1E845B3F-F58C-4C85-A818-34A067AB399FQ36132383-1A9D18F0-AF4B-420F-B1FE-76C4DDF096F3Q37687570-6C422DE4-03BF-45C6-A8BF-255DE34C9B7CQ38741932-762DCAED-3F08-4AB7-A288-CE9F67ED1B39Q38868990-C312E2F9-8841-4502-91BB-1CA7564AB8F0Q42365296-A4E6D94A-2102-4513-8DA2-53A97DAC9E7EQ48163220-E3210439-EA3E-4586-8409-B9A48FDFD271Q48192170-53B6E983-F082-4648-9F8B-FC6E8480D3F4Q52658085-41C763E4-BC84-42A2-919B-C00EFBD0735DQ55980927-875E1FBE-10D2-4EA4-BEE0-6288528BAAD4Q58696201-52CFB731-0EF0-4F69-8D79-E8EA18B562B0
P2860
The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The angular structure of ONC20 ...... s potent anti-cancer activity.
@ast
The angular structure of ONC20 ...... s potent anti-cancer activity.
@en
type
label
The angular structure of ONC20 ...... s potent anti-cancer activity.
@ast
The angular structure of ONC20 ...... s potent anti-cancer activity.
@en
prefLabel
The angular structure of ONC20 ...... s potent anti-cancer activity.
@ast
The angular structure of ONC20 ...... s potent anti-cancer activity.
@en
P2093
P2860
P356
P1433
P1476
The angular structure of ONC20 ...... s potent anti-cancer activity.
@en
P2093
Bhaskara Rao Nallaganchu
Christina Leah Kline
David T Dicker
Gary L Olson
Jessica Wagner
Joshua E Allen
Richard S Pottorf
P2860
P304
12728-12737
P356
10.18632/ONCOTARGET.2890
P407
P577
2014-12-01T00:00:00Z